FTC gives the OK for UnitedHealth's acquisition of DaVita Medical Group

dialysis
UnitedHealth's Optum unit has completed its $4.3 billion acquisition of DaVita Medical Group after getting the final OK from the Federal Trade Commission. (Getty/Jupiterimages)

UnitedHealth's Optum unit has completed its $4.3 billion acquisition of DaVita Medical Group after getting the final OK from the Federal Trade Commission (FTC).

As part of the deal, HealthCare Partners Nevada—which is DaVita Medical Group’s primary care practice in southern Nevada—will become part of Intermountain Healthcare. It was part of a settlement with the FTC to resolve allegations the acquisition could harm competition in healthcare markets in Clark and Nye counties, Nevada.

 RELATED: Optum’s $4.9B deal to buy DaVita Medical Group further expands UnitedHealth’s care delivery portfolio

Whitepaper

[Whitepaper] Analysis Shows Areas of Progress and Potential Cost Savings in Wound Care

Download this whitepaper to read the positive economic impact that digital solutions and patient engagement had on wound care patients in the home health setting who underwent negative pressure wound therapy (NPWT).

“We are excited to take this important step in building a next-generation comprehensive, coordinated health care organization. Together we will improve patient health and experiences while lowering costs across the continuum of care—including primary, specialty, urgent and surgical care,” said Andrew Witty, CEO of Optum, in a statement.

It was first announced in 2017 that Optum would acquire DaVita's medical group, one of the nation’s biggest, for $4.9 billion in cash. The company said DaVita Medical Group will join Optum’s physician-led primary, specialty, in-home, urgent and surgery care delivery services business.

Suggested Articles

Civica Rx, the non-profit generics company launched last year by hospitals, is ahead of schedule with the planned production of new drugs.

The Senate Finance Committee has finally unveiled its long-awaited legislation on drug prices. 

A Tennessee state senator and two other physicians who owned a now-closed pain clinic company were charged in a $25 million fraud case.